Towfique Raj

Towfique Raj

Auto-generated profile, based on publicly available information

Towfique Raj

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CBCéline Bellenguez
Céline Bellenguez
FKFahri Küçükali
Fahri Küçükali
IJIris E. Jansen
Iris E. Jansen
LKLuca Kleineidam
Luca Kleineidam
SMSonia Moreno-Grau
Sonia Moreno-Grau
JLJean-Charles Lambert
Jean-Charles Lambert
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

23 February 2022 in Nature
Verified
Journal Article
Open access
PDF file
ABAnna-Leigh Brown
Anna-Leigh Brown
OWOscar G. Wilkins
Oscar G. Wilkins
MKMatthew J. Keuss
Matthew J. Keuss
SHSarah E. Hill
Sarah E. Hill
MZMatteo Zanovello
Matteo Zanovello
PFPietro Fratta
Pietro Fratta
Variants of UNC13A, a critical gene for synapse function, increase the risk of amyotrophic lateral sclerosis and frontotemporal dementia1–3, two related neurodegenerative diseases defined by mislocalization of the RNA-binding protein TDP-434,5. Here we show that TDP-43 depletion induces robust inclusion of a cryptic exon in UNC13A, resulting in nonsense-mediated decay and loss of UNC13A protein. Two common intronic UNC13A polymorphisms strongly associated with amyotrophic lateral sclerosis and frontotemporal dementia risk overlap with TDP-43 binding sites. These polymorphisms potentiate cryptic exon inclusion, both in cultured cells and in brains and spinal cords from patients with these conditions. Our findings, which demonstrate a genetic link between loss of nuclear TDP-43 function and disease, reveal the mechanism by which UNC13A variants exacerbate the effects of decreased TDP-43 function. They further provide a promising therapeutic target for TDP-43 proteinopathies.

8 October 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TRTowfique Raj
Towfique Raj
YLYang I. Li
Yang I. Li
GWGarrett Wong
Garrett Wong
JHJack Humphrey
Jack Humphrey
MWMinghui Wang
Minghui Wang
PJPhilip L. De Jager
Philip L. De Jager

6 January 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KLKatia Lopes
Katia Lopes
GSGijsje J. L. Snijders
Gijsje J. L. Snijders
JHJack Humphrey
Jack Humphrey
AAAmanda Allan
Amanda Allan
MSMarjolein A. M. Sneeboer
Marjolein A. M. Sneeboer
TRTowfique Raj
Towfique Raj

2 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MPMercedes Prudencio
Mercedes Prudencio
JHJack Humphrey
Jack Humphrey
SPSarah Pickles
Sarah Pickles
ABAnna-Leigh Brown
Anna-Leigh Brown
SHSarah E. Hill
Sarah E. Hill
LPLeonard Petrucelli
Leonard Petrucelli
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 (FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2 accumulated in human induced pluripotent stem cell–derived neurons depleted of TDP-43, but not in those with pathogenic TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.

5 August 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RKRoman Kosoy
Roman Kosoy
JFJohn F. Fullard
John F. Fullard
BZBiao Zeng
Biao Zeng
JBJaroslav Bendl
Jaroslav Bendl
PDPengfei Dong
Pengfei Dong
Panos RoussosPanos Roussos
Panos Roussos